Ratings Dwarikesh Sugar Industries Limited NSE India S.E.

Equities

DWARKESH

INE366A01041

Delayed NSE India S.E. Other stock markets 04:25:46 2024-06-26 EDT			5-day change	1st Jan Change
76.44 ^INR	-0.29%		+0.13%	-12.03%

05-14	India's Dalmia Bharat Sugar fourth-quarter profit falls on weak sales	RE
04-30	Dwarikesh Sugar Industries' Profit More Than Halves in Fiscal Q4	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Food Processing

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DWARIKESH SUGAR INDUSTRIES LIMITED	-12.03%	170M		-
SÜDZUCKER AG	-2.82%	3B		B+
SÃO MARTINHO S.A.	+12.42%	2.09B		C+
SHREE RENUKA SUGARS LIMITED	+7.91%	1.31B	-	C-
BALRAMPUR CHINI MILLS LIMITED	+4.97%	1.07B		B
TRIVENI ENGINEERING & INDUSTRIES LIMITED	+15.52%	1.05B		B-
ADECOAGRO S.A.	-15.68%	973M		B
SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD.	-5.26%	921M		-
MITSUI DM SUGAR HOLDINGS CO., LTD.	+14.44%	686M	-	-
SHANDONG SANYUAN BIOTECHNOLOGY CO.,LTD.	-16.27%	680M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes